PMID- 37160564
OWN - NLM
STAT- MEDLINE
DCOM- 20240118
LR  - 20240202
IS  - 1559-0291 (Electronic)
IS  - 0273-2289 (Linking)
VI  - 196
IP  - 1
DP  - 2024 Jan
TI  - Expression and Purification of FGFR1-Fc Fusion Protein and Its Effects on Human 
      Lung Squamous Carcinoma.
PG  - 573-587
LID - 10.1007/s12010-023-04542-6 [doi]
AB  - Molecular-targeted therapies for lung squamous cell carcinoma (LSCC) are limited 
      mainly because targetable oncogenic aberrations are absent in LSCC. Recent 
      genomic analyses have revealed that the fibroblast growth factor (FGF) signaling 
      pathway plays a fundamental role in LSCC progression via cancer cell 
      proliferation and angiogenesis. In the present study, we designed, expressed, and 
      purified a fibroblast growth factor receptor fragment (FGFR1-Fc) fusion protein 
      using NS/0 cells. In FGF2-FGFR1 overexpressed NCI-H1703 cells, the FGFR1-Fc 
      fusion protein effectively inhibited proliferation and invasion and arrested the 
      cell cycle at the G0-G1 phase. In NCI-H1703 cells treated with the FGFR1-Fc 
      fusion protein, the phosphorylation levels of FGFR1, FRS2, ERK, and AKT were 
      significantly reduced. Using an siRNA assay, we demonstrated that FGF2-FGFR1 is 
      the major anti-tumor target of FGFR1-Fc fusion the FGFR1-Fc fusion protein, which 
      also significantly inhibited proliferation and invasion by NCI-H1703 cells via 
      the FGF2-FGFR1 signaling pathway. In addition, the FGFR1-Fc fusion protein 
      significantly inhibited angiogenesis in an embryonic chorioallantoic membrane 
      model. The FGFR1-Fc fusion protein may be an effective therapeutic candidate for 
      LSCC.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Zheng, Lulu
AU  - Zheng L
AD  - School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 
      325035, China.
AD  - Department of Pharmacy, Tongde Hospital of Zhejiang Province, Zhejiang, 310000, 
      Hangzhou, China.
FAU - Liu, Huan
AU  - Liu H
AD  - School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 
      325035, China.
FAU - Chen, Lingfeng
AU  - Chen L
AD  - School of Pharmaceutical Sciences, Hangzhou Medical College, Zhejiang, 310012, 
      Hangzhou, China.
FAU - You, Xinyi
AU  - You X
AD  - School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 
      325035, China.
FAU - Lv, Fangyi
AU  - Lv F
AD  - School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 
      325035, China.
FAU - Fan, Haibing
AU  - Fan H
AD  - School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 
      325035, China.
FAU - Hui, Qi
AU  - Hui Q
AD  - School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 
      325035, China. huiqi1976@163.com.
FAU - Liu, Baohua
AU  - Liu B
AD  - School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 
      325035, China. bhbh369@wmu.edu.cn.
AD  - Department of Neurological Rehabilitation, The Second Asffiliated Hospital of 
      Wenzhou Medical University, Wenzhou, 325035, China. bhbh369@wmu.edu.cn.
FAU - Wang, Xiaojie
AU  - Wang X
AD  - School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 
      325035, China. susanwang1214@wmu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20230509
PL  - United States
TA  - Appl Biochem Biotechnol
JT  - Applied biochemistry and biotechnology
JID - 8208561
RN  - CTG26PRE5S (FP-1039)
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
RN  - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 1)
RN  - EC 2.7.10.1 (FGFR1 protein, human)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Recombinant Fusion Proteins)
SB  - IM
MH  - Humans
MH  - Fibroblast Growth Factor 2
MH  - Receptor, Fibroblast Growth Factor, Type 1/genetics/metabolism
MH  - *Carcinoma, Non-Small-Cell Lung
MH  - Cell Proliferation
MH  - *Carcinoma, Squamous Cell/genetics
MH  - *Lung Neoplasms/drug therapy
MH  - Lung/metabolism
MH  - Cell Line, Tumor
MH  - *Immunoglobulin G
MH  - *Recombinant Fusion Proteins
OTO - NOTNLM
OT  - FGF2
OT  - FGFR1
OT  - FGFR1-Fc fusion protein
OT  - Squamous cell carcinoma
EDAT- 2023/05/10 00:41
MHDA- 2024/01/18 06:42
CRDT- 2023/05/09 22:50
PHST- 2023/04/11 00:00 [accepted]
PHST- 2024/01/18 06:42 [medline]
PHST- 2023/05/10 00:41 [pubmed]
PHST- 2023/05/09 22:50 [entrez]
AID - 10.1007/s12010-023-04542-6 [pii]
AID - 10.1007/s12010-023-04542-6 [doi]
PST - ppublish
SO  - Appl Biochem Biotechnol. 2024 Jan;196(1):573-587. doi: 
      10.1007/s12010-023-04542-6. Epub 2023 May 9.